Amgen (AMGN) : Zacks Investment Research ranks Amgen (AMGN) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 10 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 15 research analysts is 2.37, which indicates as a Buy.
Amgen (AMGN) : Currently there are 12 street experts covering Amgen (AMGN) stock. The most bullish and bearish price target for the stock is $201 and $157 respectively for the short term. The average price target of all the analysts comes to $184. The estimated standard deviation from the target is $14.3.
For the current week, the company shares have a recommendation consensus of Buy. Amgen (NASDAQ:AMGN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $172.24 and $171.05 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $172.78. The buying momentum continued till the end and the stock did not give up its gains. It closed at $172.43, notching a gain of 0.70% for the day. The total traded volume was 2,142,821 . The stock had closed at $171.23 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Such Annette Louise, officer (VP, Finance and CAO) of Amgen Inc, had unloaded 3,000 shares at an average price of $174.59 in a transaction dated on August 2, 2016. The total value of the transaction was worth $523,770.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.